AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03687164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Medical Visits
Description: Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
Study NCT04284150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine; Midazolam;
Description: Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
Study NCT02831907 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: All cardiac surgery procedures with the use of cardiopulmonary bypass
Study NCT02005198 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionnaire when entering the non-interventional study
Study NCT04786509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Field tests
Description: In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
Study NCT00971620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Given as an intralesional injection.
Study NCT00971620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given as an intralesional injection
Study NCT01376557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg LX4211
Description: Subjects will receive 75 mg LX4211 once daily
Study NCT01376557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg LX4211
Description: Subjects will receive 200 mg LX4211 once daily.
Study NCT01376557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg LX4211
Description: Subjects will receive 400 mg LX4211 once daily.
Study NCT01376557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg LX4211
Description: Subjects will receive 200 mg LX4211 twice daily.
Study NCT01376557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo once daily.
Study NCT02312687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRN23
Description: solution for SC injection
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV 100 mg/m2/dose on Days 1-5
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV 440 mg/m2/dose on Days 1-5
Study NCT00445445 — intervention group
Intervention type: PROCEDURE
Intervention: breast imaging study
Description: Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
Study NCT00873093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC 5 micrograms/kg/dose Only on Day 6
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given PO or IV 15mg/m2/dose q6h x 3 doses
Study NCT00445445 — intervention group
Intervention type: PROCEDURE
Intervention: radiomammography
Description: Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
Study NCT00445445 — intervention group
Intervention type: PROCEDURE
Intervention: study of high risk factors
Description: * Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~* Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
Study NCT04048317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepaSphere Microspheres/Doxorubicin Hydrochloride
Description: evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours.
Study NCT04048317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipiodol
Description: evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration
Study NCT04508790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT04508790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study NCT04508790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT00873093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose MTX
Description: IV 5000 mg/m2/dose Block 2: Day 22
Study NCT03426722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: * L-carnitine VS Placebo is randomized (1:1)~* L-carnitine 500mg TID(PO),~* First evaluation will be performed at 8 weeks and then unblinding will be done. If symptoms continue after treatment, dose escalation in L-carnitine group by 1000mg TID (PO). If symptoms continue after treatment in Placebo group, L-carnitine 500mg TID(PO) will be given.
Study NCT03426722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500mg TID(PO)
Study NCT03876769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: Based on the subject's weight, one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells
Study NCT01051765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan/cisplatin
Description: irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
Study NCT00202722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Intravenous patient controlled analgesia (ivpca) during labour
Study NCT04518631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness program
Description: The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
Study NCT05281341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: In GH groups (Group 4A \& 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B \& 3B) will receive only standard COS without GH supplementation
Study NCT03616730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NICOM (non-invasive cardiac output monitor)
Description: Transthoracic bio-reactance, or the non-invasive cardiac output measurement \[NICOMTM, Cheetah Medical Inc., Portland, OR\] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
Study NCT02217293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency
Description: Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
Study NCT01263353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR followed by Pasireotide LAR + Everolimus
Study NCT01263353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus followed by Pasireotide LAR + Everolimus
Study NCT00671320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
Study NCT00671320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
Study NCT03714685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firibastat
Description: Firibastat (QGC001) 500 mg
Study NCT01939756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravesical baobab oil
Description: Intravesical baobab oil
Study NCT03892408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow ™
Description: supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
Study NCT04406337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound
Description: Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm\^2 (0.03 W/cm\^2 ) and 20% duty cycle.
Study NCT04406337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity continuous ultrasound
Description: High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm\^2 and 100% duty cycle.
Study NCT02145793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Group Curriculum
Description: Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
Study NCT03522987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
Study NCT01620736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg po bid
Study NCT03619174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viveve Treatment
Description: The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
Study NCT03619174 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Viveve Treatment
Description: The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
Study NCT00743093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
Study NCT00743093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
Study NCT02595177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with intraocular lens implantation.
Description: Phacoemulsification under topical anesthesia with intraocular lens implantation.
Study NCT00801424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: humidified warmed CO2
Description: Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher\&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
Study NCT00793832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supervised exercise
Description: supervised exercise
Study NCT00793832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet advice
Description: Diet Advice
Study NCT00447577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate and tobramycin ophthalmic suspension
Description: Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
Study NCT00447577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin and dexamethasone ophthalmic suspension
Description: Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
Study NCT04266405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle (50 mL) per day for 28 days
Study NCT04431687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD 501
Description: QD, PO
Study NCT04266405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Cubilose Drink
Description: consume 1 bottle (50 mL) per day for 28 days
Study NCT02303405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Anti-inflammatory and anti-malarial agent
Study NCT02303405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Anti-hyperglycemic agent
Study NCT02938962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study NCT02670772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
Study NCT02670772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
Study NCT02119065 — intervention group
Intervention type: PROCEDURE
Intervention: positron emission tomography
Description: Undergo PET/CT scan
Study NCT02119065 — intervention group
Intervention type: PROCEDURE
Intervention: computed tomography
Description: Undergo PET/CT scan
Study NCT04325724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General evaluation
Description: Demographic characteristic, psoriasis duration, disease duration, treatments
Study NCT04325724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dermatological evaluation
Description: treatment and evaluation
Study NCT04325724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rheumatological evaluation
Description: joints, enthesis, tendons, and other ultrasound abnormalities
Study NCT04325724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: para clinical data
Description: biological data, medical imaging data
Study NCT04325724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient reported outcomes (PROs)
Description: Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
Study NCT04431687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759, D150
Description: QD, PO
Study NCT04006522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-Atezolizumab
Description: 89Zr-DFO-Atezolizumab infusion
Study NCT04006522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
Study NCT04836598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).
Study NCT00555139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679 tablet
Description: GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
Study NCT02821559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOMOX
Study NCT00555139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008 tablet
Description: GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
Study NCT03129022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural anaesthesia
Description: Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
Study NCT02821559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
Study NCT03956875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: yoga
Description: yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
Study NCT03956875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: yoga
Description: yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
Study NCT02413268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Study NCT02413268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Study NCT03477981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alginate bread
Description: White bread with 4% alginate (wet weight of dough) included into the bread.
Study NCT01757847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.